Lilly announces changes on board of directors
Rhea-AI Summary
Eli Lilly announced changes to its board of directors. Jon Moeller, chairman, president and CEO of Procter & Gamble, will join the board effective Dec. 1, 2024, serving on the Audit Committee and Directors and Corporate Governance Committee. Karen Walker will resign from the board effective Dec. 31, 2024, but will continue collaborating with Lilly on digital commercial activities in 2025. Walker has served since 2018 on the Audit and Talent and Compensation Committees, bringing expertise in brand-building and go-to-market strategy during a period of significant growth for Lilly.
Positive
- Addition of P&G's CEO brings strategic and operational expertise in global consumer markets
- Continued collaboration with Karen Walker on digital commercial activities maintains valuable expertise
Negative
- None.
News Market Reaction 1 Alert
On the day this news was published, LLY gained 3.25%, reflecting a moderate positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Mr. Moeller is the chairman of the board, president and chief executive officer of Procter & Gamble (P&G). A strong leader who has served as an integral part of P&G's leadership team for more than two decades, Mr. Moeller has held key positions within finance, business and strategy functions, serving as vice chairman, chief financial officer and chief operating officer, with responsibility for the company's developing markets and global operations. He also serves on the boards of the Business Roundtable, the Consumer Goods Forum, and Catalyst, a global non-profit that accelerates progress for women through workplace inclusion. Mr. Moeller will serve on the Lilly Audit Committee and the Directors and Corporate Governance Committee and will stand for election by Lilly shareholders at the company's annual meeting in May 2026.
"I am honored to welcome Jon Moeller to our board of directors," said David A. Ricks, Lilly chair and CEO. "As the CEO of an iconic American company with global reach, Jon brings deep expertise in driving strategic and operational excellence at scale. His long-standing success in leading a consumer-centric organization and providing expert counsel will offer valuable perspective to our board."
Ms. Walker has served on Lilly's board since 2018, including as a member of the board's Audit and Talent and Compensation Committees. She has brought her unique experience in brand-building and go-to-market strategy to the board during a period of significant growth for Lilly, serving as an active mentor to many of Lilly's leaders and providing valuable insight on talent development. The board and executive committee have greatly valued her perspective as an operating partner with The Goldman Sachs Group and as the former chief marketing officer of both Intel Corporation and Cisco Systems. The board also has benefited from her keen understanding of technology strategy.
"Karen has been an instrumental part of Lilly's board during her tenure, and on behalf of the entire board, I thank her for her guidance, mentorship and insights during this important period in Lilly's history," said Ricks. "We are grateful that she will continue to contribute to Lilly's growth as we scale our digital and commercial capabilities."
About Lilly
Lilly is a medicine company turning science into healing to make life better for people around the world. We've been pioneering life-changing discoveries for nearly 150 years, and today our medicines help tens of millions of people across the globe. Harnessing the power of biotechnology, chemistry and genetic medicine, our scientists are urgently advancing new discoveries to solve some of the world's most significant health challenges: redefining diabetes care; treating obesity and curtailing its most devastating long-term effects; advancing the fight against Alzheimer's disease; providing solutions to some of the most debilitating immune system disorders; and transforming the most difficult-to-treat cancers into manageable diseases. With each step toward a healthier world, we're motivated by one thing: making life better for millions more people. That includes delivering innovative clinical trials that reflect the diversity of our world and working to ensure our medicines are accessible and affordable. To learn more, visit Lilly.com and Lilly.com/news, or follow us on Facebook, Instagram, and LinkedIn. C-LLY
Refer to: | Carrie Munk; munk_carrie@lilly.com; 317-416-2393 (Media) |
Michael Czapar; czapar_michael_c@lilly.com; 317-617-0983 (Investors) |
View original content to download multimedia:https://www.prnewswire.com/news-releases/lilly-announces-changes-on-board-of-directors-302310590.html
SOURCE Eli Lilly and Company
FAQ
When will Jon Moeller join Eli Lilly's (LLY) board of directors?
Which committees will Jon Moeller serve on at Eli Lilly (LLY)?
When is Karen Walker leaving Eli Lilly's (LLY) board of directors?
What will Karen Walker's role be with Eli Lilly (LLY) in 2025?
